X-FAB Silicon Foundries (XFAB) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 revenue was $205.1M (EUR 205M), down 9% year-on-year and 4% quarter-on-quarter, within guidance; core markets contributed $190.1M, a record 94% of total revenue.
Automotive revenue grew 9% year-on-year to $142.4M, while industrial and medical segments declined 33% and 18%, respectively.
Strong bookings of $248.4M, up 12% year-on-year, with backlog at $517.3M at quarter-end.
EBITDA was $47.9M (23.3% margin), with net profit of $19.8M; cash and cash equivalents at $290.1M.
Capacity expansion continued in Malaysia and France for 200mm CMOS; SiC expansion in Texas slowed to match demand.
Financial highlights
Q2 EBITDA margin was 23.3% (22.7% excluding IFRS 15 impact); gross margin was 21.9%, down from 29.8% year-on-year.
Q2 capex was $121.9M (EUR 122M), with full-year capex expected at $550M.
Net debt improved to $(19.2)M from $(180.9)M a year ago.
Net income for Q2 was $19.8M, down from $38.7M year-on-year.
Q2 2024 capex/revenue ratio was 59.4%, up from 46.0% year-on-year.
Outlook and guidance
Q3 2024 revenue expected at $205–215M, with EBITDA margin guidance of 24–27%.
Full-year 2024 revenue guidance revised to $860–880M (from $900–970M), mainly due to delayed SiC recovery; EBITDA margin expected at 25–28%.
SiC revenue expected to recover in Q4 2024, with robust growth anticipated in 2025.
Bookings and backlog remain strong, supporting future demand.
Latest events from X-FAB Silicon Foundries
- Q4 revenue up 18% YoY to $222.3M; industrial and medical growth offset automotive softness.XFAB
Q4 20259 Feb 2026 - Q3 revenue up sequentially, China automotive strong, CapEx high, full-year guidance lowered.XFAB
Q3 202418 Jan 2026 - Double-digit growth, major expansions, and $1.5B revenue and 35% margin targeted by 2030.XFAB
Investor Day 202411 Jan 2026 - Three-pillar strategy and $1.1B expansion drive growth in specialty semiconductors.XFAB
CMD 202531 Dec 2025 - Q1 revenue up 8% sequentially, EBITDA margin 24%, guidance and expansion plans reaffirmed.XFAB
Q1 202523 Dec 2025 - 2024 saw revenue and profit declines amid destocking, but recovery and margin gains are expected.XFAB
Q4 202423 Dec 2025 - Q2 revenue up to 8% year-over-year, guidance raised, and capacity expansion completed.XFAB
Q2 202516 Nov 2025 - Q3 revenue up 11% YoY to $229M, with strong medical and industrial growth; order intake fell.XFAB
Q3 20253 Nov 2025